ArticlePrecision chemistry2025
3D Printed Microfluidic Devices for Integrated Immunoaffinity Extraction, Solid-Phase Extraction, and Fluorescent Labeling of Preterm Birth Biomarkers.
Article in Precision chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Microscale solid-phase extraction: advances in sorbent formats, system design, integration, and detection methods.Analytical and bioanalytical chemistry · 2026Review
- High-resolution 3D-printed insulator-based dielectrophoresis devices for biomolecular manipulation.Analytical and bioanalytical chemistry · 2026Article
- Article
- Microfluidic- and Field-Assisted 3D Printing: Leveraging Fluidic Control, Electrokinetic Phenomena, and Other Physical Fields to Advance Additive Manufacturing.Electrophoresis · 2025Review
- Precision Chemistry in Precision Diagnostics.Precision chemistry · 2025Article
- FieldNA: a 3D printed vertical microfluidic device for portable nucleic acid isolation from olive oil samples.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A miniaturized, biomarker-based diagnostic for preterm birth (PTB) risk will require multiple sample preparation steps to be integrated in a single platform. To this end, we created a 3D printed microfluidic device that combines immunoaffinity extraction (IAE), solid-phase extraction (SPE), and fluorescent labeling. This device uses an antibody-functionalized IAE monolith to selectively extract PTB biomarkers, a lauryl methacrylate reverse-phase SPE monolith to concentrate and facilitate fluorescent labeling of PTB biomarkers, and 3D printed valves to control flow through the monoliths. The advantageous iterative design process for arriving at a functional device is documented. The IAE/SPE device performed selective, reproducible extractions of three PTB biomarkers from buffer and depleted maternal blood serum, demonstrating its utility for single-biomarker and multiplexed extractions. After tandem extraction and fluorescent labeling, biomarkers eluted from the SPE monolith in a concentrated plug, facilitating future integration with downstream analysis techniques including microchip electrophoresis. This device effectively combines and automates orthogonal chromatographic extraction methods and constitutes a substantial step toward a complete microfluidic PTB prediction platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.